HAYWARD, Calif., Sept. 28, 2012 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012. The analysis was performed to facilitate selection of a dosing regimen to be further examined the ITCA 650 global phase 3 clinical program.
The abstract submission entitled, "Optimising phase 3 dose selection with ITCA 650: correlation between baseline HbA1c and reduction of HbA1c after 24 weeks of treatment," by R.R. Henry, J. Rosenstock, M. Baron, K. Luskey, and T. Alessi, was accepted for an oral presentation. The presenting author will be Robert R. Henry, MD, Chief of the Section of Diabetes, Endocrinology and Metabolism at the University of California, San Diego. The presentation (number 109) will take place in the Langerhans Hall, on Wednesday October 3, 2012, in Session OP 19 (Novel Therapies) from 2:30 PM - 4:00 PM Session.
About ITCA 650
ITCA 650 therapy for type 2 diabetes consists of DUROS® continuous subcutaneous delivery of exenatide. The DUROS delivery technology comprises the DUROS device, a matchstick-size, miniature osmotic pump that is placed subcutaneously to provide continuous and consistent drug therapy. Intarcia's proprietary formulation technology maintains the stability of therapeutic proteins and peptides at human body temperature for extended periods of time.
The DUROS technology can deliver up to a full year of therapy from a single ITCA 650. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady state drug delivery upon placement of ITCA 650 as well as near immediate withdrawal of therapy, if required, after its removal. ITCA 650 is an investigational new drug and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, has been approved in the United States, Europe and many other markets and is currently marketed as a twice-daily and once-weekly self-injection therapy for type 2 diabetes.
About Type 2 Diabetes
The International Diabetes Federation (IDF) estimates that 366 million people have diabetes, approximately 90% of whom have type 2 diabetes, and the number is expected to rise to 552 million by 2030. Approximately half of those affected do not even realize they have diabetes. In 2011, 4.6 million deaths were attributed to diabetes and diabetes is estimated to have resulted in $465 billion, or 11% of total healthcare expenditures, in 2011.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the efficacy, convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at human body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pursuing a clinical stage development program for type 2 diabetes and has other programs for weight regulation to control obesity.
Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation licensed to Intarcia Therapeutics, Inc. in certain fields.
SOURCE Intarcia Therapeutics, Inc.